CD276 and cancer: The nuclear transportation of PD-L1 is associated with cancer cell proliferation and the upregulation of immune checkpoint molecules such as PD-L1, PD-L2, VISTA, and B7-H3, leading to acquired resistance to PD-L1/PD-1 blockade [39, 45].